Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01963728 · ClinicalTrials.gov registry record · Phase 4
Comparison of Insulin Therapy in Treating Post-Transplant Diabetes
A Phase 4 study, sponsored by Inova Health Care Services.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT01963728 is a Phase 4 study that was terminated before completion, run by Inova Health Care Services. The registered enrollment target is 2 participants.
The verdict
NCT01963728, a Phase 4 study, was terminated before completion, sponsored by Inova Health Care Services.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
Interventions
- DRUG insulin glargine
- DRUG Insulin, Isophane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2013-11-27 |
| Est. Completion | 2015-04-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01963728
The ClinicalTrials.gov registry entry for NCT01963728 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inova Health Care Services, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which insulin glargine is the first listed.
NCT01963728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01963728 about?
NCT01963728 is a clinical study titled "Comparison of Insulin Therapy in Treating Post-Transplant Diabetes". To determine if the use of insulin isophane results in improved control of blood sugars compared to the use of insulin glargine in new onset diabetes after kidney, lung, or heart transplantation (NODAT).
What is the current status of trial NCT01963728?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2013-11-27. Estimated completion is 2015-04-09.
What interventions are being tested in trial NCT01963728?
The interventions under investigation include: insulin glargine (DRUG), Insulin, Isophane (DRUG).
Who is sponsoring clinical trial NCT01963728?
This trial is sponsored by Inova Health Care Services, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.